Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorTaipei Medical University

About this trial

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver condition linked to excess body fat, high blood lipids, and other metabolic problems. Taiwan green propolis is a natural health product collected by bees from plants, which has shown potential benefits for blood lipids and body fat in laboratory and animal studies. However, its effects in people with MASLD have not been well established in clinical trials.

This study is a double-blind, randomized, placebo-controlled trial enrolling up to 60 adults with MASLD at Dalin Tzu Chi Hospital in Taiwan. Eligible participants are randomly assigned in a 1:1 ratio to receive either Taiwan green propolis capsules or matching placebo capsules for 12 weeks. Participants take 2 capsules before breakfast and 2 capsules before dinner each day (4 capsules per day total). Neither participants nor the research team know which capsules are being taken until the study ends.

The study measures changes in blood lipids (triglycerides, total cholesterol, LDL-C, and HDL-C), body fat percentage, body weight, waist circumference, liver enzymes, blood sugar levels, inflammatory markers, and health-related quality of life. Liver fat and scarring are assessed by abdominal ultrasound before and after the intervention. Gut microbiota samples are also collected. Assessments are conducted at baseline, at 4 weeks, 8 weeks, 12 weeks (end of intervention), and at follow-up visits 2 weeks and 12 weeks after the intervention ends.

The goal of this study is to provide scientific evidence on whether Taiwan green propolis can safely and effectively improve blood lipids, body fat, and metabolic health in people with MASLD, and to explore the relationship between physiological improvements and health behavior changes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged 18 to 80 years

Overweight or obesity: BMI >= 23 kg/m²

Elevated waist circumference: >= 90 cm in men or >= 80 cm in women (South Asian and Chinese criteria)

Dysglycemia or type 2 diabetes: prediabetes (HbA1c 5.7-6.4%, or fasting glucose 100-125 mg/dL, or OGTT 2-hour glucose 140-199 mg/dL) OR type 2 diabetes (HbA1c >= 6.5%, or fasting glucose >= 126 mg/dL, or OGTT 2-hour glucose >= 200 mg/dL, or current pharmacological treatment for type 2 diabetes)

Disqualifiers

Known allergy to honey, propolis, multiple pollens, or alcohol

Psychiatric disorder or cognitive impairment

Currently pregnant or breastfeeding

Significant endocrine abnormality, or major disease of the heart, liver (other than MASLD), or kidney

Trial design

Design model

Parallel

Treatments tested in this trial

  • Taiwan green propolis capsule

    Dietary supplement

    Taiwan green propolis extract capsule taken orally, 4 capsules per day for 12 weeks.

  • Placebo capsule

    Dietary supplement

    Capsules containing edible dextrin with vitamin B2 (approximately 0.1 mg/capsule), identical in appearance and regimen to the active intervention capsules.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Taiwan Green PropolisExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in Serum Lipid Profile

Change from baseline in fasting serum triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), measured in mg/dL.

Time frame
Baseline, Week 4, Week 8, Week 12, Week 14, and Week 24
2

Change in Skeletal Muscle Mass (InBody)

Change from baseline in skeletal muscle mass measured in kilograms (kg) by InBody bioelectrical impedance analysis.

Time frame
Baseline, Week 4, Week 8, Week 12, and Week 24
3

Change in Fat Mass (InBody)

Change from baseline in total fat mass measured in kilograms (kg) by InBody bioelectrical impedance analysis.

Time frame
Baseline, Week 4, Week 8, Week 12, and Week 24
4

Change in Bone Mass (InBody)

Change from baseline in bone mass measured in kilograms (kg) by InBody bioelectrical impedance analysis.

Time frame
Baseline, Week 4, Week 8, Week 12, and Week 24

Secondary outcomes

1

Change in Waist and Hip Circumference

Change from baseline in waist circumference (cm) and hip circumference (cm) measured by tape measure.

Time frame
Baseline, Week 4, Week 8, Week 12, and Week 24
2

Change in Skinfold Thickness

Change from baseline in skinfold thickness (mm) measured at 7 body sites: chest, axilla, triceps, subscapular, abdomen, suprailiac, and thigh.

Time frame
Baseline, Week 4, Week 8, Week 12, and Week 24
3

Change in Liver Enzymes

Change from baseline in serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT), measured in U/L.

Time frame
Baseline, Week 4, Week 8, Week 12, Week 14, and Week 24
4

Change in Fasting Plasma Glucose

Change from baseline in fasting plasma glucose concentration, measured in mg/dL.

Time frame
Baseline, Week 4, Week 8, Week 12, Week 14, and Week 24

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Taipei Medical University

Lead sponsor

Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Collaborator